Samuel D. Isaly
Portfolio Manager at Eaton Vance Worldwide
Member since: Aug '04 · 4 Opinions
'%20stroke='%23F58A09'%20stroke-width='2'%3e%3cg%20id='Shopify-Inc.-Copy'%20transform='translate(120.000000,%201005.000000)'%3e%3cg%20id='Group-3'%20transform='translate(101.000000,%20209.000000)'%3e%3cg%20id='filled-.-button'%20transform='translate(597.000000,%208.000000)'%3e%3cg%20id='Group-9'%20transform='translate(16.000000,%2012.000000)'%3e%3cpath%20d='M16,6%20C16.8284271,6%2017.5784271,6.33578644%2018.1213203,6.87867966%20C18.6642136,7.42157288%2019,8.17157288%2019,9%20L19,9%20L19,15%20C19,15.8284271%2018.6642136,16.5784271%2018.1213203,17.1213203%20C17.5784271,17.6642136%2016.8284271,18%2016,18%20L16,18%20L4,18%20C3.17157288,18%202.42157288,17.6642136%201.87867966,17.1213203%20C1.33578644,16.5784271%201,15.8284271%201,15%20L1,15%20L1,9%20C1,8.17157288%201.33578644,7.42157288%201.87867966,6.87867966%20C2.42157288,6.33578644%203.17157288,6%204,6%20L4,6%20Z'%20id='Rectangle'%3e%3c/path%3e%3cpath%20d='M16,6%20C16,2.6862915%2013.3137085,0%2010,0%20C6.6862915,0%204,2.6862915%204,6'%20id='Path'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium content'%3e%3cg%20id='Rating-Card'%20transform='translate(120.000000,%20487.000000)'%3e%3cg%20id='rating-icon'%20transform='translate(72.000000,%2059.000000)'%3e%3crect%20id='Rectangle'%20fill='%23FFF2DD'%20x='0'%20y='0'%20width='22'%20height='22'%20rx='5'%3e%3c/rect%3e%3cpath%20d='M9.79206621,3.82523336%20L8.3677023,7.6173861%20L4.23899417,7.76927542%20C3.8611006,7.78313%203.50855699,7.95873057%203.27497094,8.24945155%20L3.19427794,8.36183546%20C2.85087721,8.8998309%202.97036638,9.61561086%203.49215361,10.0162546%20L6.74189548,12.5112292%20L5.61323839,16.3978487%20C5.50994169,16.7534663%205.57183795,17.1354977%205.78249243,17.4425057%20L5.8613232,17.5457315%20C6.27763024,18.0367813%207.01501318,18.149483%207.56849236,17.7865582%20L10.9994895,15.5360037%20L14.4324669,17.7865582%20C14.7465196,17.9924874%2015.1373172,18.0529952%2015.5010949,17.9520156%20L15.6258812,17.9106234%20C16.2322594,17.6753159%2016.5697685,17.0245809%2016.3877209,16.3978487%20L15.2580736,12.5112292%20L18.5088056,10.0162546%20C18.8061976,9.78790823%2018.9858275,9.44327271%2019,9.07385587%20L18.9982914,8.94504828%20C18.9567468,8.30857053%2018.4279559,7.79369241%2017.7619651,7.76927542%20L13.6322668,7.6173861%20L12.208893,3.82523336%20C12.0786387,3.47817837%2011.7988585,3.20467407%2011.4438399,3.0773415%20C10.7764516,2.837973%2010.0369273,3.17281559%209.79206621,3.82523336%20Z%20M11.0004796,6.2264738%20L12.0019841,8.89418343%20L12.0497597,9.00113138%20C12.2113724,9.3106242%2012.5330954,9.51478781%2012.8944249,9.52803511%20L15.7996792,9.63357979%20L13.5133887,11.3902783%20L13.4148721,11.4769052%20C13.1705271,11.7225786%2013.0749571,12.0800398%2013.1725066,12.4158719%20L13.9659433,15.1498005%20L11.5520384,13.5668015%20L11.4373175,13.5019775%20C11.1228001,13.3507216%2010.7455006,13.3723296%2010.4489209,13.5668015%20L8.03402575,15.1498005%20L8.8284526,12.4158719%20L8.85606782,12.2891816%20C8.90603038,11.9500269%208.76841645,11.6059202%208.48757055,11.3902783%20L6.20028992,9.63357979%20L9.10653435,9.52803511%20C9.50801159,9.51331589%209.86059183,9.26289751%209.99897515,8.89418343%20L11.0004796,6.2264738%20Z'%20id='Star'%20fill='%23FFB23E'%20fill-rule='nonzero'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Rating '%20fill='%232EC623'%3e%3cg%20id='Rating-Card'%20transform='translate(120.000000,%20487.000000)'%3e%3cg%20id='big-win-.-icon'%20transform='translate(197.000000,%2059.000000)'%3e%3crect%20id='Rectangle-Copy-7'%20fill-opacity='0.1'%20x='0'%20y='0'%20width='22'%20height='22'%20rx='5'%3e%3c/rect%3e%3cpath%20d='M11,9%20C11.5128358,9%2011.9355072,9.38604019%2011.9932723,9.88337887%20L12,10%20L12,17%20C12,17.5522847%2011.5522847,18%2011,18%20C10.4871642,18%2010.0644928,17.6139598%2010.0067277,17.1166211%20L10,17%20L10,10%20C10,9.44771525%2010.4477153,9%2011,9%20Z%20M11.5494545,4.18059717%20L11.6485991,4.26005993%20L16.6732168,8.8355974%20C17.0811864,9.20710432%2017.1112523,9.83955265%2016.7403709,10.2482103%20C16.3980187,10.6254327%2015.8337003,10.6801113%2015.4280287,10.394091%20L15.3301362,10.3154775%20L10.9760605,6.35%20L6.6698638,10.2736959%20C6.29327646,10.6166254%205.72632457,10.6173431%205.34962121,10.294004%20L5.25962914,10.2064286%20C4.91727701,9.82920619%204.9165605,9.2612982%205.23935518,8.88395957%20L5.32678318,8.79381574%20L10.3055185,4.26005993%20C10.654566,3.94220891%2011.1722936,3.91572132%2011.5494545,4.18059717%20Z'%20id='Combined-Shape'%20fill-rule='nonzero'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Big Win '%20fill='%232EC623'%3e%3cg%20id='Rating-Card'%20transform='translate(120.000000,%20487.000000)'%3e%3cg%20id='win-.-icon'%20transform='translate(322.000000,%2059.000000)'%3e%3crect%20id='Rectangle-Copy-8'%20fill-opacity='0.1'%20x='0'%20y='0'%20width='22'%20height='22'%20rx='5'%3e%3c/rect%3e%3cpath%20d='M10.3055185,7.27684696%20C10.654566,6.93847845%2011.1722936,6.91028108%2011.5494545,7.19225483%20L11.6485991,7.27684696%20L16.6732168,12.1477382%20C17.0811864,12.5432261%2017.1112523,13.2164994%2016.7403709,13.6515361%20C16.3980187,14.0531085%2015.8337003,14.1113166%2015.4280287,13.8068335%20L15.3301362,13.7231455%20L10.9760605,9.50169396%20L6.6698638,13.6786668%20C6.29327646,14.0437326%205.72632457,14.0444967%205.34962121,13.7002859%20L5.25962914,13.6070574%20C4.91727701,13.2054851%204.9165605,12.6009183%205.23935518,12.1992222%20L5.32678318,12.1032595%20L10.3055185,7.27684696%20Z'%20id='Combined-Shape-Copy'%20fill-rule='nonzero'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Win '%3e%3cg%20id='Rating-Card'%20transform='translate(120.000000,%20487.000000)'%3e%3cg%20id='neutral-.-icon'%20transform='translate(447.000000,%2059.000000)'%3e%3crect%20id='Rectangle-Copy-9'%20fill='%23F5F5F5'%20x='0'%20y='0'%20width='22'%20height='22'%20rx='5'%3e%3c/rect%3e%3cpath%20d='M17.0714286,10%20C17.5842644,10%2018,10.4477153%2018,11%20C18,11.5128358%2017.6415341,11.9355072%2017.1797196,11.9932723%20L17.0714286,12%20L5.92857143,12%20C5.41573559,12%205,11.5522847%205,11%20C5,10.4871642%205.35846589,10.0644928%205.82028038,10.0067277%20L5.92857143,10%20L17.0714286,10%20Z'%20id='Path-9'%20fill='%23979797'%20fill-rule='nonzero'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Neutral '%3e%3cg%20id='Rating-Card'%20transform='translate(120.000000,%20487.000000)'%3e%3cg%20id='loss-.-icon'%20transform='translate(572.000000,%2059.000000)'%3e%3crect%20id='Rectangle-Copy-10'%20fill='%23FFE3E1'%20x='0'%20y='0'%20width='22'%20height='22'%20rx='5'%3e%3c/rect%3e%3cpath%20d='M10.3055185,8.27684696%20C10.654566,7.93847845%2011.1722936,7.91028108%2011.5494545,8.19225483%20L11.6485991,8.27684696%20L16.6732168,13.1477382%20C17.0811864,13.5432261%2017.1112523,14.2164994%2016.7403709,14.6515361%20C16.3980187,15.0531085%2015.8337003,15.1113166%2015.4280287,14.8068335%20L15.3301362,14.7231455%20L10.9760605,10.501694%20L6.6698638,14.6786668%20C6.29327646,15.0437326%205.72632457,15.0444967%205.34962121,14.7002859%20L5.25962914,14.6070574%20C4.91727701,14.2054851%204.9165605,13.6009183%205.23935518,13.1992222%20L5.32678318,13.1032595%20L10.3055185,8.27684696%20Z'%20id='Combined-Shape-Copy-2'%20fill='%23FF4132'%20fill-rule='nonzero'%20transform='translate(11.000000,%2011.500000)%20scale(1,%20-1)%20translate(-11.000000,%20-11.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Loss '%3e%3cg%20id='Rating-Card'%20transform='translate(120.000000,%20487.000000)'%3e%3cg%20id='big-loss-.-icon'%20transform='translate(697.000000,%2059.000000)'%3e%3crect%20id='Rectangle-Copy-11'%20fill='%23FFE3E1'%20x='0'%20y='0'%20width='22'%20height='22'%20rx='5'%3e%3c/rect%3e%3cpath%20d='M11,9%20C11.5128358,9%2011.9355072,9.38604019%2011.9932723,9.88337887%20L12,10%20L12,17%20C12,17.5522847%2011.5522847,18%2011,18%20C10.4871642,18%2010.0644928,17.6139598%2010.0067277,17.1166211%20L10,17%20L10,10%20C10,9.44771525%2010.4477153,9%2011,9%20Z%20M11.5494545,4.18059717%20L11.6485991,4.26005993%20L16.6732168,8.8355974%20C17.0811864,9.20710432%2017.1112523,9.83955265%2016.7403709,10.2482103%20C16.3980187,10.6254327%2015.8337003,10.6801113%2015.4280287,10.394091%20L15.3301362,10.3154775%20L10.9760605,6.35%20L6.6698638,10.2736959%20C6.29327646,10.6166254%205.72632457,10.6173431%205.34962121,10.294004%20L5.25962914,10.2064286%20C4.91727701,9.82920619%204.9165605,9.2612982%205.23935518,8.88395957%20L5.32678318,8.79381574%20L10.3055185,4.26005993%20C10.654566,3.94220891%2011.1722936,3.91572132%2011.5494545,4.18059717%20Z'%20id='Combined-Shape-Copy-3'%20fill='%23FF4132'%20fill-rule='nonzero'%20transform='translate(11.000000,%2011.000000)%20scale(1,%20-1)%20translate(-11.000000,%20-11.000000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Big Loss '%20fill='%23000000'%3e%3cg%20id='Rating-Card'%20transform='translate(120.000000,%20487.000000)'%3e%3cpath%20d='M848.295367,82.286474%20C848.68919,81.9045087%20849.327703,81.9045087%20849.721525,82.286474%20L854,86.4361302%20L858.278475,82.286474%20C858.672297,81.9045087%20859.31081,81.9045087%20859.704633,82.286474%20C860.098456,82.6684393%20860.098456,83.2877274%20859.704633,83.6696927%20L854.35654,88.856763%20C854.159628,89.0477457%20853.840372,89.0477457%20853.64346,88.856763%20L848.295367,83.6696927%20C847.901544,83.2877274%20847.901544,82.6684393%20848.295367,82.286474%20Z'%20id='Path'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Stock Opinions by Samuel D. Isaly
TOP PICK
Growing very well. Their biggest drug is for high blood pressure but also have a good product line for cancer treatment. Not many patent exposures in the near-term.
Samuel D. IsalyOwned
biotechnologypharmaceutical
TOP PICK
TOP PICK
A very rapidly growing company. Earnings per share growth is in excess of 20% yearly. PE ratio barely more than that.
Samuel D. IsalyOwned
biotechnologypharmaceutical
TOP PICK
Has a low market cap. Have a drug that extends life in lung cancer which should be approved around the turn of the year.
Samuel D. IsalyOwned
biotechnologypharmaceutical
Showing 1 to 4 of 4 entries
- «
- ‹
- 1
- ›
- »
